NSPR InspireMD, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1433607 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY35.8%
TTM net income YoY-7.2%
TTM EPS YoY30.5%
Revenue 3-yr CAGR24.5%
Net income 3-yr CAGR—
Margins
Gross margin12.6%
Operating margin-477.8%
Net margin-469.1%
FCF margin-420.3%
EBITDA margin4,031.1%
Returns
ROE-115.4%
ROA-88.4%
ROIC (approx.)-2,478.3%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets35.2%
Debt / equity0.00x
Current ratio2.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue11.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $8.98M | $7.01M | $6.21M | $5.17M | $4.50M |
| Cost of revenue | $6.33M | $5.50M | $4.40M | $4.05M | $3.74M |
| Gross profit | $2.65M | $1.51M | $1.81M | $1.12M | $754,000 |
| R&D expense | $15.00M | $13.63M | $7.98M | $7.81M | $5.16M |
| SG&A expense | $20.71M | $15.31M | $11.10M | $8.36M | $7.41M |
| Operating income | -$49.61M | -$33.50M | -$21.14M | -$18.71M | -$14.72M |
| Pretax income | -$48.72M | -$31.95M | -$19.85M | -$18.46M | -$14.87M |
| Income tax | $63,000 | $59,000 | $65,000 | $28,000 | $45,000 |
| Net income | -$48.79M | -$32.01M | -$19.92M | -$18.49M | -$14.92M |
| EBITDA | $426.39M | $246.50M | $210.86M | $169.29M | -$14.55M |
| EPS (basic) | -0.76 | -0.76 | -0.82 | -2.35 | -2.03 |
| EPS (diluted) | -0.76 | -0.76 | -0.82 | -2.35 | -2.03 |
| Weighted avg. shares (diluted) | 64.33M | 41.93M | 24.27M | 7.87M | 7.35M |
| Balance sheet | |||||
| Cash & equivalents | $8.94M | $18.92M | $9.64M | $4.63M | $12.00M |
| Short-term investments | $45.27M | $15.72M | $29.38M | — | — |
| Receivables | $2.17M | $1.57M | $1.80M | $1.03M | $1.22M |
| Inventory | $3.40M | $2.57M | $2.11M | $1.62M | $1.14M |
| Current assets | $61.47M | $40.52M | $44.16M | $21.33M | $37.09M |
| PP&E, net | $3.58M | $2.37M | $1.06M | $917,000 | $632,000 |
| Total assets | $69.40M | $46.81M | $47.64M | $24.65M | $39.71M |
| Current liabilities | $10.71M | $7.68M | $6.02M | $5.07M | $4.35M |
| Total liabilities | $14.20M | $10.72M | $8.14M | $7.26M | $6.18M |
| Shareholders' equity | $55.20M | $36.09M | $39.50M | $17.39M | $33.53M |
| Shares outstanding | 43.53M | 26.61M | 21.84M | 8.33M | 8.30M |
| Cash flow statement | |||||
| Operating cash flow | -$35.10M | -$21.87M | -$16.38M | -$15.54M | -$13.21M |
| Capital expenditure | $1.66M | $1.40M | $381,000 | $473,000 | $344,000 |
| Free cash flow | -$36.77M | -$23.27M | -$16.76M | -$16.02M | -$13.55M |
| Investing cash flow | -$30.56M | $12.64M | -$16.09M | $8.44M | -$22.46M |
| Financing cash flow | $55.57M | $18.45M | $37.53M | -$140,000 | $35.03M |
| Depreciation & amortization | $476.00M | $280.00M | $232.00M | $188.00M | $161,000 |
| Stock-based compensation | $12.33M | $10.14M | $4.49M | $2.35M | $1.58M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.